To the Editor.—
Analyses of the risk benefit of isoniazid chemopreventive therapy like the recent thoughtful presentation by Colice1 are welcome and badly needed. However, because of certain assumptions, I believe that he overstated the justification for giving isoniazid chemopreventive therapy to many patients and understated for others.On the basis of limited data, the author calculated that the case-fatality rate for isoniazid-related hepatitis was zero with the 95% confidence intervals being 0% to 3.5%. In his comments, he pointed out that the available data supporting this contention are actually quite scanty, that the case-fatality rate is a key variable, and that giving isoniazid is not the preferred strategy when the rate is above 1%.One of the sources2 of data for his calculated value of zero should not have been included, since the patients in that study had monthly tests of liver enzymes to protect against isoniazid
Moulding T. Decision Analysis, Public Health Policy, and Isoniazid Chemoprophylaxis for Young Adult Tuberculin Skin Reactors. Arch Intern Med. 1991;151(10):2101–2105. doi:10.1001/archinte.1991.00400100151031
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: